

MAR 09 2018

SENATE CONCURRENT RESOLUTION

URGING THE UNITED STATES FOOD AND DRUG ADMINISTRATION, THE
UNITED STATES SURGEON GENERAL, AND HAWAII'S CONGRESSIONAL
DELEGATION TO CONSIDER WHETHER PRODUCTS CONTAINING
OXYBENZONE SHOULD INCLUDE A WARNING LABEL THAT ADDRESSES
HUMAN HEALTH RISKS.

1 WHEREAS, oxybenzone is a chemical commonly found in
2 sunscreen and other personal care products, and a significant
3 amount of research indicates that this chemical has negative
4 impacts on human health; and
5

6 WHEREAS, a 2002 study published in Chemico-Biological
7 Interactions showed that estrogen build-up can lead to health
8 issues, such as endometriosis and breast cancer; and
9

10 WHEREAS, a 2006 study published in The Journal of
11 Toxicological Sciences showed that oxybenzone acts as a hormone
12 mimicker, known to cause anti-androgenic and estrogenic effects,
13 such as binding of estrogen receptors and build-up of estrogen;
14 and
15

16 WHEREAS, in 2008, the Centers for Disease Control and
17 Prevention found that oxybenzone is easily absorbed by the body
18 and can accumulate in fatty tissues, such as the kidney and
19 liver; and
20

21 WHEREAS, according to a 2015 study published in
22 Chemosphere, exposure to oxybenzone in utero has been associated
23 with Hirschsprung's disease, a neonatal intestinal abnormality;
24 and
25

26 WHEREAS, a 2017 study published in Environmental Research
27 showed that oxybenzone can be transferred from mother to baby
28 via breast milk; and
29



1 WHEREAS, the most recent evaluation of the safety of
2 oxybenzone by the United States Food and Drug Administration
3 appeared in the United States Federal Register in 1999; and
4

5 WHEREAS, the United States Food and Drug Administration's
6 2011 sunscreen final rule outlines labeling requirements to
7 include warnings about the risk of skin cancer and skin aging
8 from sun exposure, and guidelines to follow to prevent and treat
9 reactions to sunscreen products; and
10

11 WHEREAS, current labeling requirements do not include
12 warnings about the potential harm to human health from
13 oxybenzone exposure; and
14

15 WHEREAS, there is no current standard for what is
16 considered a safe level of oxybenzone in the body, and no
17 special protections exist for personal care products marketed
18 toward the public, including women, babies, or children; and
19

20 WHEREAS, sunscreen and personal care products containing
21 oxybenzone should include a warning label, particularly for
22 women, pregnant or nursing mothers, and children, about the
23 potential harm from oxybenzone exposure; now, therefore,
24

25 BE IT RESOLVED by the Senate of the Twenty-ninth
26 Legislature of the State of Hawaii, Regular Session of 2018, the
27 House of Representatives concurring, that the United States Food
28 and Drug Administration, the United States Surgeon General, and
29 Hawaii's congressional delegation are urged to consider whether
30 products containing oxybenzone should include a warning label
31 that addresses the human health risks of using those personal
32 care products; and
33

34 BE IT FURTHER RESOLVED that certified copies of this
35 Concurrent Resolution be transmitted to the Commissioner of the
36 United States Food and Drug Administration, United States
37



S.C.R. NO. 172

1 Surgeon General, each member of Hawaii's congressional
2 delegation, Director of Health, and Director of Commerce and
3 Consumer Affairs.
4
5
6

OFFERED BY:

J. Kalani Egger
David K. H. Egger
BS

Dan Stutzel
Andy H. Baker
Mike Gifford
Clerencia Wiskiker
Jin
Hudson Jr

